Top

Published in:

Open Access 01-08-2020 | Insulins | Review

Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature

Authors: Leili Rahimi, Mojtaba Malek, Faramarz Ismail-Beigi, Mohammad E. Khamseh

Published in: Advances in Therapy | Issue 8/2020

Abstract

The COVID-19 outbreak was declared a pandemic on March 2020. Many patients with SARS-CoV-2 infection have underlying chronic medical conditions such as diabetes, cardiovascular disease (CVD), and hypertension. Patient-related outcomes are worse if there are associated comorbidities. We do not have enough evidence regarding the most appropriate management of patients with diabetes during COVID-19 infection. Insulin resistance and CVD together increase the inflammatory state of the body, which can contribute to and perhaps mediate the increase of COVID-19 severity. Hence, in addition to management of dysglycemia, other CVD risk factors should be targeted. We explore the possible pathophysiologic links between diabetes and COVID-19 and discuss various options to treat dysglycemia, hypertension, and dyslipidemia in the era of COVID-19.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRefPubMedPubMedCentral

Organization WH. Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. https://www.whoint/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. 2020.

Organization WH. Rolling updates on coronavirus disease (COVID-19). 2020.

Organization WH. Coronavirus disease (COVID-19) Situation Report—124, 23 May 2020.

Yanga J, Zhenga Y, Goua X, Pua K, Chena Z, Guoa Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.

Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv. 2020.

Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;28(15):12.

WHO–China Joint Mission. Report of the WHO-China Joint Mission on Corona virus Disease 2019 (COVID-19) (PDF). World Health Organization. 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.

Hespanhol V, Bárbara C. Pneumonia mortality, comorbidities matter? Pulmonology. 2020;26(3):123–9.PubMed

10.

Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci. 2017;18(3):563.PubMedCentral

11.

Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–9.PubMed

12.

Knapp S. Diabetes and infection: is there a link? A mini-review. Gerontology. 2013;59(2):99–104.PubMed

13.

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.PubMed

14.

Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–84. https://doi.org/10.1016/j.cjca.2017.12.005.CrossRefPubMed

15.

Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020. https://doi.org/10.1177/1932296820924469.CrossRefPubMedPubMedCentral

16.

Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–84.PubMed

17.

Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetology Metab Syndr. 2013;5(1):6. https://doi.org/10.1186/1758-5996-5-6.CrossRef

18.

Guimarães TA, Farias LC, Santos ES, de Carvalho Fraga CA, Orsini LA, de Freitas Teles L, et al. Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma. Oncotarget. 2016;7(34):55057–68. https://doi.org/10.18632/oncotarget.10842.CrossRefPubMedPubMedCentral

19.

Sardu C, D’Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in patients with hyperglycemia affected by Covid-19: can we do more on glycemic control? Diabetes Care. 2020. https://doi.org/10.2337/dc20-0723.CrossRefPubMedPubMedCentral

20.

Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndrome. 2013;5(1):6.

21.

Guimarães TA, Farias LC, Santos ES, de Carvalho Fraga CA, Orsini LA, de Teles Freitas L, et al. Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma. Oncotarget. 2016;7(34):55057.PubMedPubMedCentral

22.

Amin S, Lux A, O’Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. Br J Clin Pharmacol. 2019;85(1):37–46.PubMed

23.

South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084–90.PubMedPubMedCentral

24.

Liu J, Li X, Lu Q, Ren D, Sun X, Rousselle T, et al. AMPK: a balancer of the renin–angiotensin system. Biosci Rep. 2019;39(9):BSR20181994.PubMedPubMedCentral

25.

Plattner F, Bibb JA. Serine and threonine phosphorylation. Basic neurochemistry. Amsterdam: Elsevier; 2012. p. 467–92.

26.

Chen Y, Gu F, Guan J-L. Metformin might inhibit virus through increasing insulin sensitivity. Chin Med J. 2018;131(3):376–7. https://doi.org/10.4103/0366-6999.223856.CrossRefPubMedPubMedCentral

27.

Wang Y, Zhang M, Duan X, Zhou S, Ermek T, Wang Y, et al. Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro. Xi bao yu fen zi mian yi xue za zhi = Chin J Cell Mol Immunol. 2011;27(3):253–6.

28.

Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH, Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci. 2008;13:2299–310. https://doi.org/10.2741/2844.CrossRefPubMed

29.

Chen Y, Gu F, Guan J-L. Metformin might inhibit virus through increasing insulin sensitivity. Chin Med J. 2018;131(3):376.PubMedPubMedCentral

30.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369. https://doi.org/10.1136/bmj.e1369.CrossRefPubMed

31.

Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH, Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci. 2008;13(2):299.

32.

Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016;32(4):391–404.PubMed

33.

34.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMed

35.

Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.PubMed

36.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.PubMed

37.

Dekkers CC, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJ. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20(8):1988–93.PubMedPubMedCentral

38.

Kappel BA, Lehrke M, Schütt K, Artati A, Adamski J, Lebherz C, et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation. 2017;136(10):969–72.PubMed

39.

Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, et al. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017;18(5):1083.PubMedCentral

40.

Cure E, Cure MC. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndrome. 2020;14(4):405.

41.

Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diabetes Rep. 2019;19(12):151.

42.

Xu J, Wei G, Wang J, Zhu J, Yu M, Zeng X, Wang H, Xie W, Kong H. Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharideinduced acute lung injury in mice via maintenance of endothelial barrier function. Lab Invest. 2019;99(4):577–87. https://doi.org/10.1038/s41374-018-0170-0.CrossRefPubMed

43.

Kutsukake M, Matsutani T, Tamura K, Matsuda A, Kobayashi M, Tachikawa E, et al. Pioglitazone attenuates lung injury by modulating adipose inflammation. J Surg Res. 2014;189(2):295–303.PubMed

44.

Zhang W, Li C, Liu B, Wu R, Zou N, Xu Y-Z, et al. Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. Ann Hepatol. 2013;12(6):892–900.PubMed

45.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775.CrossRefPubMedCentralPubMed

46.

Salvetti A, Brogi G, Di Legge V, Bernini G. The inter-relationship between insulin resistance and hypertension. Drugs. 1993;46(Suppl 2):149–59. https://doi.org/10.2165/00003495-199300462-00024.CrossRefPubMed

47.

Rajpal A, Rahimi L, Ismail-Beigi F. COVID-19 and diabetes: factors leading to high morbidity and mortality. J Diabetes (Submitted).

48.

Tikellis C, Thomas M. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Peptides. 2012;2012:256294. https://doi.org/10.1155/2012/256294.CrossRef

49.

Salvetti A, Brogi G, Di Legge V, Bernini G. The inter-relationship between insulin resistance and hypertension. Drugs. 1993;46(2):149–59.PubMed

50.

Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–43. https://doi.org/10.1074/jbc.M200581200.CrossRefPubMed

51.

Tikellis C, Thomas M. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012.

52.

Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009;2(5):446–55.PubMed

53.

54.

Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020;297:1–2.

55.

Simoes e Silva A, Silveira K, Ferreira A, Teixeira M. ACE2, angiotensin-(1–7) and M as receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169(3):477–92.PubMedPubMedCentral

56.

Brett AS, Rind DM. ACE inhibitors and ARBs during the COVID-19 pandemic. NEJM Journal Watch. April 9, 2020. https://www.jwatch.org/na51345/2020/04/09/ace-inhibitors-and-arbs-during-covid-19-pandemic.

57.

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10. https://doi.org/10.1161/CIRCULATIONAHA.104.510461.CrossRefPubMed

58.

Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125:21–38.PubMedPubMedCentral

59.

Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–6.PubMed

60.

61.

Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020;83(3):217.PubMedPubMedCentral

62.

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020:102433.

63.

Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.PubMed

64.

Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends Immunol. 2014;35(6):253–61. https://doi.org/10.1016/j.it.2014.02.007.CrossRefPubMedPubMedCentral

65.

Kim HJ, Han SJ, Kim DJ, Jang HC, Lim S, Choi SH, et al. Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. Korean J Intern Med. 2017;32(3):497–504. https://doi.org/10.3904/kjim.2015.404.CrossRefPubMed

66.

Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671–81. https://doi.org/10.1161/CIRCRESAHA.120.317134.CrossRefPubMedPubMedCentral

67.

Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends Immunol. 2014;35(6):253–61.PubMedPubMedCentral

68.

69.

Coppola S, Froio S, Chiumello D. β-blockers in critically ill patients: from physiology to clinical evidence. Crit Care. 2015;19(1):119. https://doi.org/10.1186/s13054-015-0803-2.CrossRefPubMedPubMedCentral

70.

Tan K, Harazim M, Tang B, Mclean A, Nalos M. The association between premorbid beta blocker exposure and mortality in sepsis—a systematic review. Crit Care. 2019;23(1):298.PubMedPubMedCentral

71.

Al-Qadi MO, Kashyap R. A42 ARDS: RISK, TREATMENT, AND OUTCOMES: effect of chronic beta blockers use on sepsis-related acute respiratory distress syndrome. Am J Respir Crit Care Med. 2015;191:1.

72.

Coppola S, Froio S, Chiumello D. β-blockers in critically ill patients: from physiology to clinical evidence. Annual Update in Intensive Care and Emergency Medicine 2015: Springer; 2015. p. 139–52.

73.

Vasanthakumar N. Can beta-adrenergic blockers be used in the treatment of COVID-19? Med Hypotheses. 2020;5(142):109809.

74.

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020.

75.

Kazory A, Ronco C, McCullough PA, editors. SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill. Baylor University Medical Center Proceedings; 2020: Taylor & Francis.

76.

Vincent J-L, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726–34.PubMed

77.

Khawaja AP, Warwick AN, Hysi PG, Kastner A, Dick A, Khaw PT, et al. Associations with covid-19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study. medRxiv. 2020.

78.

Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, et al. Role of drugs affecting the renin–angiotensin–aldosterone system on susceptibility and severity of COVID-19: a large case-control study from Zheijang Province, China. medRxiv. 2020.

79.

Zheng S, Xu H, Zhou H, Ren X, Han T, Chen Y, et al. Associations of lipid profiles with insulin resistance and β cell function in adults with normal glucose tolerance and different categories of impaired glucose regulation. PLOS ONE. 2017;12(2):e0172221. https://doi.org/10.1371/journal.pone.0172221.eCollection.2017.CrossRefPubMedPubMedCentral

80.

Olejnik J, Hume AJ, Mühlberger E. Toll-like receptor 4 in acute viral infection: Too much of a good thing. PLoS Pathog. 2018;14(12):e1007390. https://doi.org/10.1371/journal.ppat.1007390.CrossRefPubMedPubMedCentral

81.

Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.PubMedPubMedCentral

82.

Shin YH, Min JJ, Lee J-H, Kim E-H, Kim GE, Kim MH, et al. The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. Heart Vessels. 2017;32(5):618–27. https://doi.org/10.1007/s00380-016-0936-5.CrossRefPubMed

83.

Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. 2020. https://doi.org/10.1016/j.jaut.2020.102463.CrossRefPubMedPubMedCentral

84.

Diamantis E, Kyriakos G, Victoria Quiles-Sanchez L, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev. 2017;13(3):209–16.PubMedPubMedCentral

85.

86.

Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. 2020:102463.

87.

Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2(3):355–74.PubMedPubMedCentral

88.

Kim NH, Kim SG. Fibrates revisited: potential role in cardiovascular risk reduction. Diabetes Metab J. 2020;44(2):213.PubMedPubMedCentral

89.

Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75(3):645–62.PubMedPubMedCentral

90.

Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with metabolic syndrome. J Clin Endocrinol Metab. 2010;95(2):829–36.PubMedPubMedCentral

91.

Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950.PubMedPubMedCentral

92.

Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thromb. 2020. https://doi.org/10.1007/s11239-020-02138-z.CrossRef

Title: Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
Authors: Leili Rahimi
Mojtaba Malek
Faramarz Ismail-Beigi
Mohammad E. Khamseh
Publication date: 01-08-2020
Publisher: Springer Healthcare
Keywords: Insulins
SARS-CoV-2
COVID-19
Hypertension
Insulins
Hypertension
Published in: Advances in Therapy / Issue 8/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-020-01417-8

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature

Abstract

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial

Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran

Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries

Primary Care Physicians’ Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey

Correction to: Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page